Excessive Daytime Fatigue
FDA OKs supplemental NDA for Lumryz in patients aged 7 years and older with narcolepsy
The FDA has approved a supplemental new drug application for a once-daily, extended-release therapeutic to treat cataplexy or excessive daytime sleepiness in patients with narcolepsy aged 7 years and older, according to the manufacturer.
Sunosi 'likely superior' treatment for daytime sleepiness in patients with sleep apnea
Sunosi, Wakix and armodafinil-modafinil reduced excessive daytime sleepiness in patients with obstructive sleep apnea who are already receiving conventional therapy, with Sunosi being “likely superior,” according to researchers.
Combination pramipexole, rasagiline reduced daytime sleepiness in adults with early PD
BOSTON — Treatment with an investigational combination of low-dose pramipexole and rasagiline led to less excessive daytime sleepiness and fewer adverse events compared with pramipexole alone in early Parkinson’s disease, research showed.
Despite current therapies, challenges remain when treating excessive daytime sleepiness
Excessive daytime sleepiness is a common symptom of several sleep disorders, including obstructive sleep apnea, which is estimated to affect 10% to 30% of adults in the U.S and often goes underdiagnosed, according to the Sleep Foundation.
Aculys Pharma initiates phase 3 trial for excessive daytime sleepiness treatment
Aculys Pharma, Inc. announced the initiation of a phase 3 trial of pitolisant, a histamine H3 receptor antagonist/inverse agonist in those with excessive daytime sleepiness that is associated with obstructive sleep apnea syndrome.
FDA grants tentative approval for daytime sleepiness treatment
The FDA has granted tentative approval to Lumryz, a once-at-bedtime oral treatment for excessive daytime sleepiness or cataplexy in adults with narcolepsy, Avadel Pharmaceuticals announced in a press release.